IndusInd Bank Regulatory Approval

IndusInd Bank Results Update

IndusInd Bank's Q2 FY27 press release reports net profit of ₹1,242 crore versus a prior-year loss. Gross NPA improved to 2.73% from 3.60%.

IndusInd Bank Investor Presentation: Key Takeaways

Q2FY27 PAT ₹1,242cr (+20% QoQ) and operating profit ₹2,874cr (+40% YoY), driven by loan growth and better asset quality. NIM fell to 3.23% from 3.57% QoQ. GNPA 2.73%, CRAR 16.59%.

IndusInd Bank Management Change

IndusInd Bank appointed Ms. Priyanka Sinha as Non-Executive Independent Director for four years from 23 Oct 2026, subject to shareholder approval. The filing is a Regulation 30 disclosure with her profile attached.

IndusInd Bank Q2 FY27 Results: Turns Profitable, Net Profit ₹1,242 Cr

IndusInd Bank Ltd reported revenue from operations of ₹11,796 Cr (+1.6% YoY) and net profit of ₹1,242 Cr for Q2 FY27.

Key figure

Net profit ₹1,242 Cr

IndusInd Bank Employee Stock Options

IndusInd Bank's Compensation Committee approved 1,00,000 stock options to 11 employees under its ESOP scheme. Grant price is Rs. 849.55 with 3-year vesting.

IndusInd Bank Other Announcement

The company has filed its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with SEBI regulatory requirements.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.